1. United States Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
GOLDENWELL BIOTECH INC.

GOLDENWELL BIOTECH INC.

OOTC:GWLL
0.65
USD
0.00
(0.00%)
0.00EPS
51.48MMarket Cap
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
-0.01
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
-0.01
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
96
91
96
99
99
99
98
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
-740.7
-2,060.89
-6,308.61
-88,559.71
-206,047.27
-208,729.09
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
-1
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-732.64
-2,060.87
-6,392.21
-94,602.88
-539,038.18
-512,940
Working Capital
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-42.52
-391.43
-82.11
- -
- -
- -

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
99
99
99
Market Capitalization
287
99
51

Working Capital

USD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
80.3%
627.57%
Free Cash Flow
- -
680.87%
-81.61%
Net Income, GAAP
- -
508.26%
125.46%
Sales/Revenue/Turnover
- -
- -
-60.43%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Shuang Liu
Full Time Employees
3
Sector
Health technology
Industry
Pharmaceuticals: other
Address
7316 Capilano Dr. Solon OH United States 44139
IPO Date
Dec 7, 2021
CIK
0001800373
Website
goldenwellbiotech.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Goldenwell Biotech, Inc. (GWLL) develops and manufactures nutraceutical and dietary supplements in the United States. The company offers JI MAI, a bovine cardiac vascular active peptide; Cartilage Peptide, a type II collagen peptide; Double Proline AG 3D active collagen peptide; DNA repair tablets; and Sugar Master tablets. Goldenwell Biotech, Inc. operates in the personal care products industry within the household sector, targeting health-conscious consumers with peptide-based supplements for vascular health, joint support, skin care, cellular repair, and blood sugar management. Founded in 2019 and headquartered at 581 Boston Mills Road, Suite 300, Hudson, Ohio 44236, the company maintains customizable manufacturing facilities to ensure product quality and holds international and domestic technology patents. No major acquisitions, partnerships, funding rounds, or product launches have been publicly reported in the last 1-2 years.